The firm will use the proceeds to develop and commercialize its lead drug for depression, fund clinical trials for it coronary vasodilator, and other things.
The firm's full-year revenues were up 26 percent, according to the preliminary results. It also expects to offer all remaining shares of common stock on its existing shelf registration statement.
The placing and an open offer could raise up to £6.9 million which would be used to see the company through to breakeven/profitability.
The firm will use the proceeds from the offering for product development efforts and to further its efforts to obtain US Food and Drug Administration clearance of its stool-based DNA colorectal cancer screening product.
The firm will use the proceeds to fund further development of its stool-based DNA colorectal cancer screening product.
The shelf registration is tied to Life Technologies' acquisition late last year of BioTrove.
The microRNA-based molecular diagnostics developer plans to use earnings from the sale of securities for a range of corporate purposes.
Helicos will use the funds for R&D efforts and general corporate purposes. Its shares tumbled in response to the offering.
The firm will apply the proceeds primarily to its drug development efforts.
The firm sold 5.4 million shares at $7 per share.
In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.
Canadian regulators are beginning to share information from new drug studies, Undark reports.
In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.
Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.